share_log

Results: Intuitive Surgical, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Results: Intuitive Surgical, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

業績:Intuitive Surgical, Inc. 超出盈利預期,分析師現在有了新的預測
Simply Wall St ·  04/20 08:36

Shareholders might have noticed that Intuitive Surgical, Inc. (NASDAQ:ISRG) filed its first-quarter result this time last week. The early response was not positive, with shares down 4.8% to US$366 in the past week. Revenues were US$1.9b, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$1.51, an impressive 29% ahead of estimates. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

股東們可能已經注意到,Intuitive Surgical, Inc.(納斯達克股票代碼:ISRG)上週這個時候公佈了第一季度業績。早期的反應並不樂觀,過去一週股價下跌4.8%,至366美元。收入爲19億美元,與分析師的預期大致一致,儘管法定每股收益(EPS)打破了預期,爲1.51美元,比預期高出29%,令人印象深刻。根據結果,分析師更新了他們的盈利模式,很高興知道他們是否認爲公司的前景發生了巨大變化,或者業務是否照舊。根據這些結果,我們收集了最新的法定預測,以了解分析師是否改變了盈利模式。

earnings-and-revenue-growth
NasdaqGS:ISRG Earnings and Revenue Growth April 20th 2024
NASDAQGS: ISRG 收益和收入增長 2024 年 4 月 20 日

Following the latest results, Intuitive Surgical's 28 analysts are now forecasting revenues of US$8.02b in 2024. This would be a meaningful 9.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are forecast to decrease 4.3% to US$5.36 in the same period. In the lead-up to this report, the analysts had been modelling revenues of US$8.00b and earnings per share (EPS) of US$5.14 in 2024. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

根據最新業績,Intuitive Surgical的28位分析師現在預測2024年的收入爲80.2億美元。與過去12個月相比,這將使收入顯著增長9.6%。預計同期法定每股收益將下降4.3%,至5.36美元。在本報告發布之前,分析師一直在模擬2024年的收入爲800億美元,每股收益(EPS)爲5.14美元。從他們新的每股收益估計來看,分析師似乎對該業務更加看好。

There's been no major changes to the consensus price target of US$419, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Intuitive Surgical analyst has a price target of US$475 per share, while the most pessimistic values it at US$253. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

419美元的共識目標股價沒有重大變化,這表明每股收益前景的改善不足以對該股估值產生長期的積極影響。但是,固定單一價格目標可能是不明智的,因爲共識目標實際上是分析師目標股價的平均值。因此,一些投資者喜歡查看估計範圍,看看對公司的估值是否有任何分歧。最樂觀的Intuitive Surgical分析師將目標股價定爲每股475美元,而最悲觀的分析師則將其目標股價定爲253美元。對該股肯定有一些不同的看法,但在我們看來,估計範圍還不夠廣,不足以暗示情況不可預測。

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 13% growth on an annualised basis. That is in line with its 13% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.0% per year. So it's pretty clear that Intuitive Surgical is forecast to grow substantially faster than its industry.

了解這些預測的更多背景信息的一種方法是研究它們與過去的業績相比如何,以及同一行業中其他公司的表現。分析師表示,截至2024年底將帶來更多相同的情況,收入按年計算預計將增長13%。這與其在過去五年中13%的年增長率一致。相比之下,我們的數據表明,預計類似行業的其他公司(有分析師報道)的收入每年將增長8.0%。因此,很明顯,預計Intuitive Surgical的增長速度將大大快於其行業。

The Bottom Line

底線

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Intuitive Surgical's earnings potential next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at US$419, with the latest estimates not enough to have an impact on their price targets.

對我們來說,最大的收穫是共識的每股收益上調,這表明人們對Intuitive Surgical明年盈利潛力的看法明顯改善。令人高興的是,收入預測沒有重大變化,預計該業務的增長速度仍將快於整個行業。共識目標股價穩定在419美元,最新估計不足以對其目標價格產生影響。

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Intuitive Surgical going out to 2026, and you can see them free on our platform here..

話雖如此,公司收益的長期軌跡比明年重要得多。在Simply Wall St,我們有分析師對到2026年的Intuitive Surgical的全方位估計,你可以在我們的平台上免費查看。

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

需要考慮的另一件事是管理層和董事最近是否在買入或賣出股票。我們在此處概述了過去十二個月在我們的平台上所有公開市場股票交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論